

Consolidated Financial Results for the third Quarter of FY2019

Consolidated Subsidiaries: 2

ASKA Pharma Medical Co., Ltd. / ASKA Animal Health Co., Ltd.

	FY2018 Q3 Apr. 2018-Dec. 2018		FY2019 Q3 Apr. 2019-Dec. 2019		YoY
	Millions of Yen	Ratio	Millions of Yen	Ratio	
Net Sales	37,016	100.0%	41,207	100.0%	11.3%
Cost of Sales	22,027	59.5%	22,643	54.9%	2.8%
Gross Profit	14,988	40.5%	18,563	45.0%	23.9%
Selling, General and Administrative Expenses	12,404	33.5%	17,043	41.4%	37.4%
Operating Income	2,578	7.0%	1,520	3.7%	- 41.0%
Profit Attributable to Owners of Parent	2,216	6.0%	1,064	2.6%	- 52.0%

Forecast of Consolidated Financial Results for the FY2019

	FY2018 Actual Apr. 2018-Mar. 2019		FY2019 Forecast Apr. 2019-Mar. 2020		YoY
	Millions of Yen	Ratio	Millions of Yen	Ratio	
Net Sales	46,706	100.0%	53,000	100.0%	13.5%
Operating Income	1,782	3.8%	2,000	3.8%	12.2%
Profit Attributable to Owners of Parent	1,744	3.7%	1,000	1.9%	- 42.7%

Sales of Main Products

(Billions of yen)

Therapeutic Category	Products	FY2018 Actual	FY2019 Actual	FY2019 Forecast
Antihypertensive agent	CANDESARTAN*	9.42	10.48	13.60
Thyroid hormone	THYRADIN	4.58	5.37	6.98
LH-RH derivative	LEUPRORELIN	3.27	3.79	4.52
Poorly absorbable rifamycin antimicrobial agent	RIFXIMA	1.90	2.92	3.89
Dysmenorrhea agent	FREWELL	0.46	1.67	2.01
GnRH antagonist	RELUMINA	-	1.64	1.98
Antihypertensive agent	AMLODIPINE	1.09	1.16	1.53
Hyperlipidemic agent	LIPDIL	1.64	1.13	1.21
Antithyroid agent	MERCAZOLE	0.92	1.08	1.34
Prostate cancer therapeutic agent	BICALUTAMIDE	0.96	1.01	1.06

*Including CANDESARTAN formulation's sales